Annual Total Long Term Liabilities
$9.07 M
-$13.10 M-59.08%
December 31, 2023
Summary
- As of March 10, 2025, AVTX annual total long term liabilities is $9.07 million, with the most recent change of -$13.10 million (-59.08%) on December 31, 2023.
- During the last 3 years, AVTX annual total long term liabilities has risen by +$5.10 million (+128.60%).
- AVTX annual total long term liabilities is now -75.64% below its all-time high of $37.24 million, reached on December 31, 2021.
Performance
AVTX Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$16.70 M
-$8.81 M-34.54%
September 30, 2024
Summary
- As of March 10, 2025, AVTX quarterly total long term liabilities is $16.70 million, with the most recent change of -$8.81 million (-34.54%) on September 30, 2024.
- Over the past year, AVTX quarterly long term liabilities has stayed the same.
- AVTX quarterly long term liabilities is now -55.65% below its all-time high of $37.66 million, reached on March 31, 2022.
Performance
AVTX Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
AVTX Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -59.1% | 0.0% |
| 3 y3 years | +128.6% | 0.0% |
| 5 y5 years | -60.8% | 0.0% |
AVTX Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -75.6% | at low | -55.6% | +94.9% |
| 5 y | 5-year | -75.6% | +207.2% | -55.6% | +465.7% |
| alltime | all time | -75.6% | +625.7% | -55.6% | +1545.5% |
Avalo Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $16.70 M(-34.5%) |
| Jun 2024 | - | $25.52 M(+180.0%) |
| Mar 2024 | - | $9.11 M(+0.5%) |
| Dec 2023 | $9.07 M(-59.1%) | $9.07 M(+5.8%) |
| Sep 2023 | - | $8.57 M(-2.1%) |
| Jun 2023 | - | $8.75 M(-54.6%) |
| Mar 2023 | - | $19.26 M(-13.1%) |
| Dec 2022 | $22.17 M(-40.5%) | $22.17 M(+8.5%) |
| Sep 2022 | - | $20.43 M(-10.3%) |
| Jun 2022 | - | $22.78 M(-39.5%) |
| Mar 2022 | - | $37.66 M(+1.1%) |
| Dec 2021 | $37.24 M(+838.6%) | $37.24 M(+3.4%) |
| Sep 2021 | - | $36.01 M(+72.9%) |
| Jun 2021 | - | $20.82 M(+443.7%) |
| Mar 2021 | - | $3.83 M(-3.5%) |
| Dec 2020 | $3.97 M(+34.4%) | $3.97 M(-2.0%) |
| Sep 2020 | - | $4.05 M(+0.4%) |
| Jun 2020 | - | $4.03 M(+25.9%) |
| Mar 2020 | - | $3.20 M(+8.4%) |
| Dec 2019 | $2.95 M | $2.95 M(-86.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $21.71 M(-6.3%) |
| Jun 2019 | - | $23.16 M(-1.9%) |
| Mar 2019 | - | $23.61 M(+2.1%) |
| Dec 2018 | $23.13 M(+499.4%) | $23.13 M(-0.3%) |
| Sep 2018 | - | $23.19 M(-2.9%) |
| Jun 2018 | - | $23.88 M(-8.1%) |
| Mar 2018 | - | $25.99 M(+573.6%) |
| Dec 2017 | $3.86 M(+208.6%) | $3.86 M(+208.6%) |
| Sep 2017 | - | $1.25 M(0.0%) |
| Jun 2017 | - | $1.25 M(0.0%) |
| Mar 2017 | - | $1.25 M(0.0%) |
| Dec 2016 | $1.25 M(-54.1%) | $1.25 M(-16.7%) |
| Sep 2016 | - | $1.50 M(+47.8%) |
| Jun 2016 | - | $1.02 M(-45.9%) |
| Mar 2016 | - | $1.88 M(-31.1%) |
| Dec 2015 | $2.72 M(-91.9%) | $2.72 M(-91.4%) |
| Sep 2015 | - | $31.65 M(+673.0%) |
| Jun 2015 | - | $4.09 M(-87.6%) |
| Mar 2015 | - | $32.94 M(-2.1%) |
| Dec 2014 | $33.65 M(+69.5%) | $33.65 M |
| Dec 2013 | $19.86 M | - |
FAQ
- What is Avalo Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Avalo Therapeutics?
- What is Avalo Therapeutics annual total long term liabilities year-on-year change?
- What is Avalo Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Avalo Therapeutics?
- What is Avalo Therapeutics quarterly long term liabilities year-on-year change?
What is Avalo Therapeutics annual total long term liabilities?
The current annual total long term liabilities of AVTX is $9.07 M
What is the all time high annual total long term liabilities for Avalo Therapeutics?
Avalo Therapeutics all-time high annual total long term liabilities is $37.24 M
What is Avalo Therapeutics annual total long term liabilities year-on-year change?
Over the past year, AVTX annual total long term liabilities has changed by -$13.10 M (-59.08%)
What is Avalo Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of AVTX is $16.70 M
What is the all time high quarterly long term liabilities for Avalo Therapeutics?
Avalo Therapeutics all-time high quarterly total long term liabilities is $37.66 M
What is Avalo Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, AVTX quarterly total long term liabilities has changed by $0.00 (0.00%)